Glivec (imatinib) CML and GIST Treatment Glivec, CML, and GIST Treatment Information for International Healthcare Professionals Glivec, CML and GIST Treatment Information for US Residents International Glivec Information from Novartis Oncology Click here to go to Novartis.com Novartis Oncology International Site
International Glivec Information from Novartis Oncology
Ask a question
Haematology and Oncology News from Glivec.com

Our weekly newsletter keeps you informed of the latest haematology and oncology news.

Help us improve Glivec.com.
Please take our short survey.

Print Glivec Information from Novartis Oncology emial
 

1. Glivec Summary of Product Characteristics [SMPC]. Basel, Switzerland: Novartis Pharma AG; 2005.

2. Druker BJ, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine.(2007 April).

 

Disclaimer: This is an international website for Glivec (imatinib) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the For US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.



Use of this website is subject to our Terms of Use.
© 2008 Novartis Pharma AG